An investigation on behalf of investors of Rockwell Medical, Inc. (NASDAQ: RMTI) shares over potential securities laws violations by Rockwell Medical, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Rockwell Medical, Inc. (NASDAQ: RMTI) concerning whether a series of statements by Rockwell Medical, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Wixom, MI based Rockwell Medical, Inc. operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. Rockwell Medical, Inc. reported that its annual Total Revenue rose from $53.28 million in 2016 to $57.3 million in 2017 and that its Net Loss increased from $19.8 million in 2016 to $25.92 million in 2017.

On May 22, 2018, Rockwell Medical, Inc announced that the Companys President and Chief Executive Officer, Robert Chioini, had been terminated from his positions, effective immediately.

However, on May 23, 2018, a letter to shareholders was published on behalf of Mr. Chioini explaining that Mr. Chioini had called an emergency Board meeting for the purpose of discussing alleged breaches of fiduciary duties and other possible violations of securities laws by various directors the Company, and that those directors whose conduct was the subject of the alleged breaches of fiduciary duties voted to fire Mr. Chioini.